ArchiMed
PE
2014
$9 000 M
New York, New York, United States
Profile
ArchiMed is a healthcare-focused private equity investor based in Europe, established by healthcare professionals. The firm consists of over 160 professionals, including finance experts, scientists, and operational managers. They distinguish themselves by accelerating the development of healthcare industries and solutions that benefit people and patients around the world. ArchiMed is known for its team’s ability to leverage their scientific and operational expertise to foster growth in their portfolio companies.
ArchiMed invests exclusively in the healthcare sector, covering sub-sectors such as pharmaceuticals, medical devices, and healthcare services. The firm generally targets leveraged buyouts with check sizes typically in the $50-100 million range. The structured stages include acquisitions, and series B investments within North America and Europe. They manage several funds, including the MED Platform I and MED Platform II funds, summing up to significant assets under management.
Notable investments include Esperion Therapeutics - biopharmaceuticals, Cardioline - cardiovascular monitoring, Corealis - pharmaceutical solutions, and IRAB - science and technology development. Their strategic acquisitions and impactful healthcare investments emphasize their prowess in the sector.
Industry
ArchiMed Funds
| Name | Type |
|
|
|
Size | AUM | Launch date |
|---|---|---|---|---|---|---|---|
|
MED I
|
Private Equity (PE)
|
Financial Services
Fintech
Healthcare Services
SaaS
Software
HealthTech
|
Series B
Late Stage (Series C+)
|
North America
Europe
|
$5-10 m
|
$155 M
|
December 2014
|
|
MED Platform II Fund
|
Private Equity (PE)
|
Biotechnology
Healthcare Services
Medical Devices
Pharmaceuticals
HealthTech
|
Series B
Late Stage (Series C+)
|
North America
Europe
|
$50-100 m
|
—
|
August 2026
|
|
MED Platform II
|
Private Equity (PE)
|
Transportation
Software
Security
Pharmaceuticals
Medical Devices
Healthcare Services
Foodtech
Food and Beverage
Fintech
Financial Services
Edtech
Education
Business Services (B2B)
Biotechnology
HealthTech
LegalTech
MedTech
|
Series B
Late Stage (Series C+)
|
Europe
North America
|
$50-100 m
|
$3500 M
|
June 2023
|
